Opinion of the Transparency Council – enoxaparinum natricum and nadroparinum calcicum
At its meeting on 26 August 2024, the Transparency Council adopted opinion No. 141/2024 on the inclusion in the reimbursement of medicines containing the active substances enoxaparinum natricum and nadroparinum calcicum in the scope of indications for use or dosage or method of administration different from those specified in the Summary of Product Characteristics